AstraZeneca PLC $AZN Position Increased by Triad Wealth Partners LLC

Triad Wealth Partners LLC lifted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 23.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 3,418 shares of the company’s stock after buying an additional 651 shares during the quarter. Triad Wealth Partners LLC’s holdings in AstraZeneca were worth $239,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Goldman Sachs Group Inc. boosted its stake in AstraZeneca by 30.9% in the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after acquiring an additional 3,224,251 shares during the period. American Century Companies Inc. boosted its position in AstraZeneca by 406.9% during the 1st quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock valued at $148,517,000 after purchasing an additional 1,621,974 shares during the period. Boston Partners grew its stake in AstraZeneca by 35.9% during the 1st quarter. Boston Partners now owns 5,036,645 shares of the company’s stock worth $368,712,000 after buying an additional 1,329,166 shares during the last quarter. Deutsche Bank AG increased its position in AstraZeneca by 650.1% in the first quarter. Deutsche Bank AG now owns 1,234,847 shares of the company’s stock worth $90,761,000 after buying an additional 1,070,223 shares during the period. Finally, Invesco Ltd. lifted its stake in AstraZeneca by 33.2% in the first quarter. Invesco Ltd. now owns 3,807,522 shares of the company’s stock valued at $279,853,000 after buying an additional 948,659 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of AZN opened at $85.31 on Friday. The firm has a market capitalization of $264.58 billion, a PE ratio of 32.07, a P/E/G ratio of 1.54 and a beta of 0.36. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $78.04 and a 200 day moving average price of $73.10. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $85.50.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. During the same period in the prior year, the business posted $1.24 EPS. The business’s revenue for the quarter was up 16.1% compared to the same quarter last year. On average, sell-side analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is presently 37.97%.

Analyst Ratings Changes

AZN has been the subject of several recent research reports. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Saturday, September 27th. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.